In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes

A Regulatory Science Perspective on Warfarin Therapy: A Pharmacogenetic Opportunity

(2009) Myong-Jin Kim et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The largest prospective warfarin-treated cohort supports genetic forecasting

(2008) M. Wadelius et al.   BLOOD

Antithrombotic Therapy in Neonates and Children

(2008) Paul Monagle et al.   CHEST

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

(2008) BF Gage et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genetic Determinants of Response to Warfarin during Initial Anticoagulation

(2008) Ute I. Schwarz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics

(2008) Hedi Schelleman et al.   PHARMACOGENOMICS

Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations

(2008) Alan HB Wu et al.   PHARMACOGENOMICS

Influence ofCYP2C9andVKORC1on warfarin dose, anticoagulation attainment and maintenance among European–Americans and African–Americans

(2008) Nita A Limdi et al.   PHARMACOGENOMICS

Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer

(2007) Ellen Ruud et al.   PEDIATRIC BLOOD & CANCER